Machine signal
Active cluster sell — 3 distinct insiders, $23M, window ends Nov 2, 2026.
Figures computed from official regulatory filings — .
Analysttarget 1,463.4 USD (+9%) · consensus 4.35/5 · 25 buy · 4 hold · 2 sell
Ownershipinsiders 0.28% · institutions 85.73% · short 0.8% of float · 2.84d to cover
In USD · as of Nov 16, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ELI LILLY & Co only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Market information source · Nov 16, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Nov 16, 2026
Purchases and sales · full history
35 buys11,153 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Moeller Jon R | Award | $240K | Unusual size | SEC | |
| Kaelin William G Jr | Award | $240K | SEC | ||
| GREENE GABRIELLE Etrack record | Award | $5K | SEC | ||
| LUCIANO JUAN Rtrack record | Award | $15.9K | SEC | ||
| Baicker Katherine | Award | $240K | SEC | ||
| Hedley Mary Lynne | Award | $240K | Unusual size | SEC | |
| Fyrwald J Eriktrack record | Award | $240K | Unusual size | SEC | |
| JOHNSON KIMBERLY H | Award | $240K | Unusual size | SEC | |
| Alvarez Ralph | Award | $12.4K | SEC | ||
| Bertozzi Carolyn R | Award | $254.5K | Unusual size | SEC | |
| Alvarez Ralph | Award | $240K | Unusual size | SEC | |
| LUCIANO JUAN Rtrack record | Award | $240K | Unusual size | SEC | |
| GREENE GABRIELLE Etrack record | Award | $240K | Unusual size | SEC | |
| Fyrwald J Eriktrack record | Award | $9.9K | SEC | ||
| JACKSON JAMERE | Award | $240K | Unusual size | SEC | |
| Jonsson Patrik | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Ricks David Atrack record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Montarce Lucas | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Skovronsky Daniel | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Montarce Lucas | Other | $960.5K | SEC | ||
| Brown Adrienne S | Other | $1.6M | SEC | ||
| Dozier Eric | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Custer Kenneth L. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Custer Kenneth L. | Other | $2M | SEC | ||
| Montarce Lucas | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |